Abstract
B-type natriuretic peptide (BNP), initially identified in brain tissues, is now recognized as a key cardiac hormone. Numerous studies over the last decade have demonstrated that both exogenous and endogenous BNP prevent left ventricular (LV) hypertrophy in experimental settings, largely via activation of particulate guanylyl cyclase (pGC)-coupled receptors. BNP represents somewhat of a paradox, in that upregulation of BNP expression is widely used as a diagnostic marker for LV hypertrophy, diastolic dysfunction and heart failure in the clinic. We and others have postulated that BNP serves as an endogenous brake on the LV myocardium, seeking to curb the runaway train of signaling pathways that drive the progression from LV hypertrophy though remodeling, heart failure and death. This review summarizes the mechanisms of BNPs antihypertrophic actions, the role for cyclic GMP-mediated inhibition of pro-hypertrophic signaling, and BNPs impact on LV function. The improved understanding of the mechanisms of BNP regulation of LV hypertrophy and function that has emerged from both the experimental and clinical experience with this peptide provides new insight into the potential that BNP pharmacotherapy still offers for patients with LV hypertrophy.
Keywords: BNP, cardiomyocyte, cyclic GMP, hypertrophy, natriuretic peptides, nesiritide
Current Molecular Medicine
Title: B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Volume: 9 Issue: 7
Author(s): Rebecca H. Ritchie, Anke C. Rosenkranz and David M. Kaye
Affiliation:
Keywords: BNP, cardiomyocyte, cyclic GMP, hypertrophy, natriuretic peptides, nesiritide
Abstract: B-type natriuretic peptide (BNP), initially identified in brain tissues, is now recognized as a key cardiac hormone. Numerous studies over the last decade have demonstrated that both exogenous and endogenous BNP prevent left ventricular (LV) hypertrophy in experimental settings, largely via activation of particulate guanylyl cyclase (pGC)-coupled receptors. BNP represents somewhat of a paradox, in that upregulation of BNP expression is widely used as a diagnostic marker for LV hypertrophy, diastolic dysfunction and heart failure in the clinic. We and others have postulated that BNP serves as an endogenous brake on the LV myocardium, seeking to curb the runaway train of signaling pathways that drive the progression from LV hypertrophy though remodeling, heart failure and death. This review summarizes the mechanisms of BNPs antihypertrophic actions, the role for cyclic GMP-mediated inhibition of pro-hypertrophic signaling, and BNPs impact on LV function. The improved understanding of the mechanisms of BNP regulation of LV hypertrophy and function that has emerged from both the experimental and clinical experience with this peptide provides new insight into the potential that BNP pharmacotherapy still offers for patients with LV hypertrophy.
Export Options
About this article
Cite this article as:
Ritchie H. Rebecca, Rosenkranz C. Anke and Kaye M. David, B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target, Current Molecular Medicine 2009; 9 (7) . https://dx.doi.org/10.2174/156652409789105499
DOI https://dx.doi.org/10.2174/156652409789105499 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biology of Cholesterol Lowering in Atherosclerotic Plaques
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adeno-Associated Viral Vectors for Retinal Gene Transfer and Treatment of Retinal Diseases
Current Gene Therapy The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Inhibition of IκB Phosphorylation by a Novel IKK Inhibitor IMD-1041 Attenuates Myocardial Dysfunction After Infarction
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy Tissue Doppler Imaging: Beautiful Noise
Current Cardiology Reviews Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Novel Insights into the Pervasive Role of M3 Muscarinic Receptor in Cardiac Diseases
Current Drug Targets Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy Pleiotropic Effects of ARB in Vascular Metabolism - Focusing on Atherosclerosis-Based Cardiovascular Disease
Current Vascular Pharmacology Synthesis of New Antibacterial Cubane-based Nanocomposite and its Application in Combination Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Value of Sodium-Glucose Co-Transporter 2 Inhibitor Versus Traditional Medication in Microalbuminuric Diabetic Patients
Current Diabetes Reviews Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Beta-Blockers and Cardiovascular Outcomes in Acute Heart Failure with a History of Coronary Artery Disease and an Ejection Fraction ≥ 40%
Current Vascular Pharmacology Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy